About this Research Topic
The tumor immune microenvironment (TIME) and cell apoptosis share a complex relationship, forming a crucial aspect of tumor immunity. TIME comprises immune cells, tumor cells, and immune molecules interacting to regulate immune cell activity and apoptosis in tumors.
Cell apoptosis, vital for tumor immunity, is a programmed cell death process that eliminates unwanted cells. Tumor cells resist apoptosis through mechanisms like increasing anti-apoptotic proteins or reducing pro-apoptotic protein production. Inducing apoptosis is key to eliminating tumor cells and reducing the tumor burden. Additionally, apoptotic cells release antigens stimulating immune responses, aiding immune-mediated attacks on tumors.
Cancer genetics and oncogenomics play a significant role in shaping the relationship between TIME and cell apoptosis or cell death. The genetic alterations within tumor cells can influence the susceptibility of cells to apoptosis or cell death and modulate the immune response. By elucidating these molecular mechanisms, researchers can develop strategies to enhance the capacity of immune cells to induce apoptosis/cell death in tumor cells, ultimately improving the effectiveness of tumor immunotherapy approaches.
Therefore, the focus of this research topic is to explore the interplay between TIME and apoptosis or cell death and delve deeply into the molecular mechanisms of cell apoptosis or cell death within TIME from the perspectives of genetics and genomics. It will also introduce relevant therapeutic strategies and potential personalized treatment approaches, offering novel insights and directions for cancer immunotherapy.
We welcome submissions of original research papers, reviews, case reports, clinical trials, data reports, hypotheses & theories, methods, and opinions, including (but not limited to) research on the following sub-themes:
• Genetic alterations and apoptosis or cell death: investigating genetic mutations impacting cell apoptosis or cell death regulation in cancer cells within TIME.
• Oncogenic pathways and apoptotic signaling: exploring dysregulated oncogenic pathways that promote tumor survival by evading cell death mechanisms through apoptotic signaling.
• Immune checkpoints and apoptosis Resistance: Examining how immune checkpoint molecules modulate apoptotic pathways within TIME.
• Biomarkers for apoptosis or cell death modulation: identifying and validating predictive biomarkers for therapies targeting apoptotic or cell death pathways, emphasizing personalized treatment approaches.
• Immunotherapy strategies targeting apoptosis or cell death: discussing novel immunotherapeutic approaches utilizing cancer genetics and oncogenomics to enhance treatment outcomes by promoting cell apoptosis or cell death in TIME.
Please NOTE: We welcome bioinformatic studies, but we caution against relying solely on publicly available datasets like TCGA for analysis，without accompanying validation (either through an independent cohort or biological validation in vitro or in vivo). such manuscripts will not be accepted as part of this research topic.
Cell apoptosis, vital for tumor immunity, is a programmed cell death process that eliminates unwanted cells. Tumor cells resist apoptosis through mechanisms like increasing anti-apoptotic proteins or reducing pro-apoptotic protein production. Inducing apoptosis is key to eliminating tumor cells and reducing the tumor burden. Additionally, apoptotic cells release antigens stimulating immune responses, aiding immune-mediated attacks on tumors.
Cancer genetics and oncogenomics play a significant role in shaping the relationship between TIME and cell apoptosis or cell death. The genetic alterations within tumor cells can influence the susceptibility of cells to apoptosis or cell death and modulate the immune response. By elucidating these molecular mechanisms, researchers can develop strategies to enhance the capacity of immune cells to induce apoptosis/cell death in tumor cells, ultimately improving the effectiveness of tumor immunotherapy approaches.
Therefore, the focus of this research topic is to explore the interplay between TIME and apoptosis or cell death and delve deeply into the molecular mechanisms of cell apoptosis or cell death within TIME from the perspectives of genetics and genomics. It will also introduce relevant therapeutic strategies and potential personalized treatment approaches, offering novel insights and directions for cancer immunotherapy.
We welcome submissions of original research papers, reviews, case reports, clinical trials, data reports, hypotheses & theories, methods, and opinions, including (but not limited to) research on the following sub-themes:
• Genetic alterations and apoptosis or cell death: investigating genetic mutations impacting cell apoptosis or cell death regulation in cancer cells within TIME.
• Oncogenic pathways and apoptotic signaling: exploring dysregulated oncogenic pathways that promote tumor survival by evading cell death mechanisms through apoptotic signaling.
• Immune checkpoints and apoptosis Resistance: Examining how immune checkpoint molecules modulate apoptotic pathways within TIME.
• Biomarkers for apoptosis or cell death modulation: identifying and validating predictive biomarkers for therapies targeting apoptotic or cell death pathways, emphasizing personalized treatment approaches.
• Immunotherapy strategies targeting apoptosis or cell death: discussing novel immunotherapeutic approaches utilizing cancer genetics and oncogenomics to enhance treatment outcomes by promoting cell apoptosis or cell death in TIME.
Please NOTE: We welcome bioinformatic studies, but we caution against relying solely on publicly available datasets like TCGA for analysis，without accompanying validation (either through an independent cohort or biological validation in vitro or in vivo). such manuscripts will not be accepted as part of this research topic.
Keywords: Cancer, Tumor, Cell Apoptosis, Tumor Immune Microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
